Share
About Event
Pavel Krejčí is specializing in genetic disorders affecting bone growth. He completed his Bc. and MSc. degrees at Masaryk University, where he focused on biological sciences. He went on to earn his Ph.D. in medical sciences, specializing in genetics and molecular biology. Pavel gained international experience working at Cedars-Sinai Medical Center and UCLA in the U.S., where he developed expertise in genetic disorders. After returning to Brno, he established the "Cell Signaling" research group at the Department of Biology, Faculty of Medicine. His research has contributed to the development of vosoritide, a drug approved in the EU and USA to promote bone growth in children with achondroplasia. Krejčí’s work also focuses on the development of aptamers to target the FGFR3 gene, some of which are now in clinical trials for achondroplasia. Krejčí has received numerous awards, including recognition from the Czech Academy of Sciences. His work continues to advance treatments for genetic disorders and improve patient outcomes globally.
